News By Wire

The Future Looks Green for Eurofins

The UK’s leader in food and water testing is driving forward with its goal of becoming completely carbon neutral by 2026 thanks to the delivery of its first two electric vehicles.

Eurofins Food and Water Testing UK & Ireland has added the electric variants to its existing nationwide fleet of collection vehicles – the first of many investments which will see the company gradually replace its fuel-operated fleet over the next four years.

Mark Carnaghan, Managing Director, explained: “Our business’s DNA is centred on continuous improvement and innovation, and ensuring that our entire service offering meets the changing needs of our customers.

“The new vehicles will allow us to test and measure capabilities and performance across our South of England collection routes and provide us with valuable insight into any future improvements we can make as we continue to roll out our fleet replacement framework in the years to come.”

As part of Eurofins’ drive to become carbon neutral by 2026, the UK & Ireland food and water businesses have welcomed further significant investment with the opening in late 2021 of two new, high specification sites in Cork and near Heathrow.

“Reducing our impact on the environment forms an important part of our exciting five-year strategy and in enhancing the Eurofins experience for our teams and stakeholders across the country.

“From investment in our labs, to operational workflows, energy usage and electric vehicles, it’s vital that we continue innovating and utilising the latest technologies at our disposal to continue building a business that is fit for the future.”

Press release information


Image File:


Area / Region:

Notes to editors

Notes to Editors: For more information, please visit or contact: Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620 E-mail: [email protected] About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research services. Eurofins is also one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, BioPharma Contract Development and Manufacturing, advanced material sciences and in the support of clinical studies. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. With 58,000 staff across a decentralised and entrepreneurial network of 900 laboratories in 54 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products. The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world. In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19. Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP). Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended. Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.

Media contact

Media contact name:

Jennie Lloyd

Media contact business / organisation:

Zen Communications

Media contact telephone:

07947 085426

Media contact email:

All done!
Thank you for subscribing.

Email Subscription